EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma

Anna Lundahl, Rod Hughes iD, Joachim Almquist iD, David Close, Jukka Mäenpää, Ulrika Tehler, Tina Jellesmark Jensen, Szilárd Nemes, Anne-Kristina Mercier iD, Zala Jevnikar, Pablo Forte Soto, Dave Singh iD

British Journal of Clinical Pharmacology · 2026-01 · 92 (1) · 257-268

DOI: 10.1002/bcp.70262 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 30.08.2025. Verfasst von Anna Lundahl und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Asthma, Janus Kinase 1, Anti-Asthmatic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute for Health Research, Manchester Biomedical Research Centre, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1‐dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a novel JAK1 selective inhibitor, following inhaled (dry powder, nebulized) and intravenous administration to healthy participants and patients with mild asthma.

Methods

This was a randomized, single‐blind, placebo‐controlled Phase 1 study (NCT03766399) of single‐ and multiple‐ascending doses conducted using a three‐part design. Healthy participants and patients with mild asthma aged 18–55 years were recruited. The study evaluated safety, tolerability, PK and PD of AZD0449. PD was measured as the effect on fractional exhaled nitric oxide (FeNO). Systemic target engagement was measured using phosphorylation of signal transducer and activator of transcription 6 (pSTAT6).

Results

A total of 125 participants were included in the study. No drug‐related safety concerns emerged. Following inhaled administration, AZD0449 showed low, dose‐proportional, systemic exposures and elimination from plasma was partly absorption‐limited, suggesting lung retention and supporting once‐daily dosing. At the dose levels evaluated (1.2–5.0 mg), there was no significant anti‐inflammatory effect (reduction in FeNO) with AZD0449 vs . placebo, following repeated dosing for 14 days. Furthermore, there was no significant suppression of pSTAT6.

Conclusions

AZD0449 was safely administered via inhalation, with low systemic exposure and lung retention. This study provides a greater understanding of inhaled dosing of small molecule JAK1 inhibitors for the treatment of asthma. No effect on PD biomarkers (FeNO and STAT6) was observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaJanus Kinase 1Anti-Asthmatic AgentsHumansAdultMaleFemaleAdministration, InhalationMiddle AgedYoung AdultSingle-Blind MethodAdolescentDose-Response Relationship, DrugHealthy VolunteersSTAT6 Transcription Factor

Stichwörter der Autor:innen

JAK inhibitorsasthmainflammationnitric oxidepharmacokinetics

Substanzen

Janus Kinase 1JAK1 protein, humanAnti-Asthmatic AgentsSTAT6 protein, humanSTAT6 Transcription Factor

Autor:innen und Institutionen

  • Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Research and Early Development, Respiratory and Immunology, AstraZeneca, Cambridge, UK.
  • Chief Medical Office, Research & Development, Patient Safety Biopharma, AstraZeneca, Gothenburg, Sweden.
  • Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Early Respiratory and Immunology Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Early Biostats & Statistical Innovation, Data Science & AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Rod Hughes, Joachim Almquist, Anne-Kristina Mercier, Dave Singh

Förderung

  • National Institute for Health Research
  • Manchester Biomedical Research Centre
  • AstraZeneca

Zitieren

APA

Lundahl, A., Hughes, R., Almquist, J., Close, D., Mäenpää, J., Tehler, U., Jensen, T. J., Nemes, S., Mercier, A. K., Jevnikar, Z., Soto, P. F., & Singh, D. (2026). AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma. British Journal of Clinical Pharmacology, 92(1), 257-268. https://doi.org/10.1002/bcp.70262

Vancouver

Lundahl A, Hughes R, Almquist J, Close D, Mäenpää J, Tehler U, et al. AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma. British Journal of Clinical Pharmacology. 2026;92(1):257-268. doi:10.1002/bcp.70262

BibTeX
@article{Lundahl2026,
  author = {Lundahl, Anna and Hughes, Rod and Almquist, Joachim and Close, David and Mäenpää, Jukka and Tehler, Ulrika and Jensen, Tina Jellesmark and Nemes, Szilárd and Mercier, Anne-Kristina and Jevnikar, Zala and Soto, Pablo Forte and Singh, Dave},
  title = {AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  volume = {92},
  number = {1},
  pages = {257--268},
  doi = {10.1002/bcp.70262}
}
Kostenlos starten →